Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hehir

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Muscle & Nerve|August 2, 2022
Re: Diagnosing myasthenia gravis in older patients: Comments and observationsIkjae Lee, Jesse D Schold, Michael K Hehir, et al.
Muscle & Nerve|May 15, 2012
Unexpected neuroimaging abnormalities in patients with apparent C8 radiculopathy: broadening the clinical spectrumMichael K Hehir, Juan J Figueroa, Andrea M Zynda-Weiss, et al.
Muscle & Nerve|April 21, 2010
Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patientsMichael K Hehir, Ted M Burns, Joshua Alpers, et al.
Muscle & Nerve|October 17, 2025
Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia GravisYuebing Li, David Bruckman, Jesse D Schold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1991
Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptorC W Shearman, D Pollock, G White, et al.
Neurology|November 4, 2024
Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019David Bruckman, Ikjae Lee, Jesse D Schold, et al.
Journal of Biomolecular Structure & Dynamics|December 1, 1983
The lambda and P22 phage repressorsR T Sauer, H C Nelson, K Hehir, et al.
Biochemistry|October 7, 1986
An engineered intersubunit disulfide enhances the stability and DNA binding of the N-terminal domain of lambda repressorR T Sauer, K Hehir, R S Stearman, et al.
Muscle & Nerve|September 7, 2023
Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU)Michael K Hehir, Mark Conaway, Avery B St Sauveur, et al.
Plos One|February 17, 2022
The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse eventsMichael K Hehir, Mark Conaway, Eric M Clark, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Muscle & Nerve|August 2, 2022
Re: Diagnosing myasthenia gravis in older patients: Comments and observationsIkjae Lee, Jesse D Schold, Michael K Hehir, et al.
Muscle & Nerve|May 15, 2012
Unexpected neuroimaging abnormalities in patients with apparent C8 radiculopathy: broadening the clinical spectrumMichael K Hehir, Juan J Figueroa, Andrea M Zynda-Weiss, et al.
Muscle & Nerve|April 21, 2010
Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patientsMichael K Hehir, Ted M Burns, Joshua Alpers, et al.
Muscle & Nerve|October 17, 2025
Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia GravisYuebing Li, David Bruckman, Jesse D Schold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1991
Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptorC W Shearman, D Pollock, G White, et al.
Neurology|November 4, 2024
Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019David Bruckman, Ikjae Lee, Jesse D Schold, et al.
Journal of Biomolecular Structure & Dynamics|December 1, 1983
The lambda and P22 phage repressorsR T Sauer, H C Nelson, K Hehir, et al.
Biochemistry|October 7, 1986
An engineered intersubunit disulfide enhances the stability and DNA binding of the N-terminal domain of lambda repressorR T Sauer, K Hehir, R S Stearman, et al.
Muscle & Nerve|September 7, 2023
Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU)Michael K Hehir, Mark Conaway, Avery B St Sauveur, et al.
Plos One|February 17, 2022
The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse eventsMichael K Hehir, Mark Conaway, Eric M Clark, et al.
Pageof 5